drugset

drugset / Trial / NCT03187262

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

NCT03187262 ↗

Phase 2 Completed 13 enrolled Dana-Farber Cancer Institute Janssen, LP · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.

Timeline

Start: 2017-11-27
Primary completion: 2021-01-31
Completion: 2021-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daratumumab	Monoclonal antibody	—	—

Indications